Purchase Order 75N95020P00144
Award Date
3/27/20
Potential Completion Date
6/30/20
Potential Value
$47K
Funding Federal Agency
National Center for Advancing Translational Sciences
Contracting Federal Agency
National Institute on Drug Abuse
Awardee
Southern Research Institute
Ultimate Awardee
Not listed
NAICS Category
541380 - Testing Laboratories and Services
PSC Category
Q301 - Reference Laboratory Testing
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Birmingham, AL 35205, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $37,000 firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to Southern Research Institute. The contract is for COVID-19 compound testing and cytotoxicity screening in the SARS-CoV-2 CPE assay. This non-competitive award was made under simplified acquisition procedures, with the vendor selected due to prior work on the compound testing. The period of performance runs through...
This firm fixed-price purchase order was awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to Southern Research Institute to conduct COVID-19 compound testing and cytotoxicity screening in the SARS-CoV-2 cytopathic effect (CPE) assay across two rounds. The $74,000.00 contract has an ultimate completion date of August 28, 2020 and was not set aside for any specific business type. Southern Research Institute is a...
This is a $37,000.00 firm fixed price purchase order contract awarded by the National Center for Advancing Translational Sciences, part of the U.S. Department of Health and Human Services, to Southern Research Institute, a non-profit research organization, for compound testing and cytotoxicity screening related to SARS-CoV-2. The contract does not have a set-aside designation. Through past federal contracts and grants, Southern Research has provided a range of research and development services...
This federal contract award, valued at $79,000.00, was issued by the National Center for Advancing Translational Sciences (NCATS), a civilian agency, to the Southern Research Institute, a non-profit organization, for "HIGH-THROUGHPUT SARS-COV-2 ALPHALISA SCREENING FOR COVID-19 DRUG DISCOVERY - ANTIVIRAL INITIATIVE". The contract has a firm fixed price and was awarded on a non-competitive basis with no set-aside designation. Based on the agency and description, this contract supports...
This is a firm fixed-price purchase order awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, a civilian agency, to Southern Research Institute, a non-profit organization, for $7,500.00. The purpose is to conduct testing of MAP30-TAT x dexamethasone samples to evaluate their inhibition of COVID-19 binding to the ACE2 receptor in cell culture. This award is not associated with a set-aside program. Southern Research Institute has experience providing a range of...
This $136,000 firm fixed price purchase order was awarded by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Southern Research Institute, a non-profit research organization, to screen assay-ready plates in a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nanoluc reporter virus (NLRV) assay. The contract supports the Antiviral Program for Pandemics (APP) initiative to develop treatments for SARS-CoV-2 and other coronaviruses,...
This is a firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to Southern Research Institute for $27,500.00. The contract is for assay development to measure the SARS-CoV-2 antiviral effect of remdesivir and the development of an AlphaLISA assay to be conducted under biosafety level 3 (BSL-3) conditions. This non-competitive contract was awarded without full and open competition due to...
This is a $8,755.00 firm fixed price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Southern Research Institute, a non-profit research organization. The contract has no set-aside designation and was awarded on August 15, 2012, with a completion date of November 30, 2012. Southern Research Institute, doing business as Southern Research, has experience providing drug discovery and development, infectious disease research, and other...
This is a $37,522 Firm Fixed Price delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Southern Research Institute, a corporate entity tax-exempt non-profit organization. The contract is to provide in vitro assessment for antimicrobial activity, and is part of the broader In Vitro Antimicrobial Assessments 2011-2018 IDIQ contract vehicle. Southern Research Institute has extensive experience providing research and development...
This is a $544,000.00 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to Southern Research Institute, a corporate entity tax-exempt non-profit organization. The contract is for biomedical (applied/exploratory) research and does not have a set-aside designation. Through this contract, Southern Research Institute is providing a range of services, including drug discovery and...